ENDRA Life Sciences (NASDAQ:NDRA) Trading 3.3% Higher – Still a Buy?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares traded up 3.3% during mid-day trading on Tuesday . The company traded as high as $5.13 and last traded at $4.95. 10,183 shares traded hands during trading, a decline of 79% from the average session volume of 47,782 shares. The stock had previously closed at $4.79.

Analyst Ratings Changes

Several analysts recently commented on the stock. Ascendiant Capital Markets reduced their price target on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, ENDRA Life Sciences presently has a consensus rating of “Hold” and an average target price of $25.00.

ENDRA Life Sciences Price Performance

The company has a 50 day moving average price of $5.04 and a 200 day moving average price of $4.57. The firm has a market cap of $6.29 million, a PE ratio of -0.61 and a beta of -0.06.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.14. On average, equities analysts anticipate that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC acquired a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up approximately 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. 1.19% of the stock is owned by hedge funds and other institutional investors.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.